• 1
    Guañabens N, Cerdá D, Monegal A, Pons F, Caballería LL, Peris P, et al. Low bone mass and severity of choslestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology 2010:138:2348-2356.
  • 2
    Menon KW, Angulo P, Weston ER, Dickson KD, Lindor J. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 2001;35:316-323.
  • 3
    Floreani A, Chiaramonte M, Giannini S, Malvasi L, Lodetti MG, Castrignano R, et al. Longitudinal study on osteodystrophy in primary biliary cirrhosis (PBC) and a pilot study on calcitonin treatment. J Hepatol 1991;12:217-223.
  • 4
    Guañabens N, Parés A, del Rio L, Roca M, Gómez R, Muñoz J, et al. Sodium fluoride prevents bone loss in primary biliary cirrhosis. J Hepatol 1992;15:345-349.
  • 5
    Boone RH, Cheung AM, Girlan LM, Heathcote EJ. Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin. Dig Dis Sci 2006;51:1103-1112.
  • 6
    Ormasdóttir S, Mallmin H, Naessén T, Petrén-Mallmin M, Broomé U, Hultcrantz R, et al. An open, randomized, controlled study of transdermal hormonal replacement therapy on the rate of bone loss in primary biliary cirrhosis. J Int Med 2004;256:63-69.
  • 7
    Levy C, Harnois DM, Angulo P, Jorgensen R, Lindor KD. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int 2005;25:117-121.
  • 8
    Guañabens N, Pares A, Monegal A, Peris P, Pons F, Alvarez L, et al. Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years. Gastroenterology 1997;113:219-224.
  • 9
    Guañabens N, Parés A, Ros I, Alvarez L, Pons F, Caballeria LL, et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 2003;98:2268-2274.
    Direct Link:
  • 10
    Lindor KD, Jorgensen RA, Tiegs RD, Khosla S, Dickson RE. Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. J Hepatol 2000;33:878-882.
  • 11
    Zein CO, Jorgensen RA, Clarke B, Wenger DE, Keach JC, Angulo P, et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 2005;42:762-771.
  • 12
    Wolfhagen FHJ, van Buuren HR, den Ouden JW, Hop WCJ, van Leeuwen JPTM, Schalm SW, et al. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. J Hepatol 1997;26:325-330.
  • 13
    Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis—for whom and for how long? N Engl J Med 2012;366:2051-2053.
  • 14
    Pares A, Cerda D, Monegal A, Muxí A, Caballeria LL, Peris P, et al. Monthly ibandronate vs weekly alendronate in the treatment of osteoporosis associated with primary biliary cirrhosis. Similar efficacy but different adherence. J Hepatol 2010;52(Suppl 1):S79.
  • 15
    Rudic JS, Giljaca V, Krstic MN, Bjelakovic C, Gluud C. Bisphosphonates for osteoporosis in primary biliary cirrhosis. Cochrane Database Syst Rev 2011;12:CD009144.
  • 16
    Kanis JA. Treatment of generalized osteoporosis with inhibitors of bone resorption. In: Kanis KA, ed. Osteoporosis. Oxford, UK: Blackwell Science; 1994. p 168-195.
  • 17
    Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-759.
  • 18
    Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005;20:1315-1322.
  • 19
    International Osteoporosis Foundation. The adherence gap: why osteoporosis patients don't continue with treatment. Available at: , 2005.
  • 20
    Chesnut CH III, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-1249.
  • 21
    World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843. Geneva: WHO; 1994.
  • 22
    Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24:67-74.
  • 23
    Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 2002;50(Suppl 1):1-9.
  • 24
    Leslie WD, Bernstein CN, Leboff MS; American Gastroenterological Association Clinical Practice Commitee. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003;125:941-966.
  • 25
    Guañabens N, Parés A. Liver and bone. Arch Biochem Biophys 2010;503:84-94.
  • 26
    Parés A, Guañabens N. Treatment of bone disorders in liver disease. J Hepatol 2006;45:445-453.
  • 27
    Atamaz F, Hepguler S, Akyildiz M, Karasu Z, Kilic M. Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation. Osteoporos Int 2006;17:942-949.
  • 28
    Reginster JY, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone 2006;38(Suppl 1):S2-S6.
  • 29
    Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007;18:1023-1031.
  • 30
    Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-1460.
  • 31
    Regynster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:654-661.
  • 32
    Lin T, Wang C, Cai XZ, Zhao X, Shi MM, Ying ZM, et al. Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis. Int J Clin Pract 2012;66:399-408.
  • 33
    Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 2000;12:1-12.
  • 34
    Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD, et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2007;92:1296-1304.
  • 35
    Peris P, Martinez-Ferrer A, Monegal A, Martinez de Osaba MJ, Muxi A, Guañabens N. 25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis. Bone 2012;51:54-58.
  • 36
    Cryer B, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 2002;77:1031-1043.
  • 37
    Collier J. Bone disorders in chronic liver disease. Hepatology 2007;46:1271-1278.
  • 38
    Treeprasertsuk S, Silveira MG, Petz JL, Lindor KD. Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis. Am J Ther 2011;18:375-381.
  • 39
    Guañabens N, Monegal A, Muxí A, Martinez-Ferrer A, Reyes R, Caballería J, et al. Patients with cirrhosis and ascites have false values of bone density. Osteoporos Int 2012;23:1481-1487.